A new gene therapy has emerged as a ray of hope for patients suffering from the serious eye disease Retinitis Pigmentosa. American biotech company Nanoscope Therapeutics has developed optogenetic gene therapy named MOGENRY. In clinical trials, this treatment has shown improvement in the visual ability of some patients.
This disease gradually damages the light sensing cells of the retina i.e. photoreceptors. Over time, the patient's vision may weaken and in severe cases, blindness may occur. The specialty of MOGENRY is that instead of repairing the damaged cells, it tries to make the remaining cells in the retina sensitive to light.
What is MOGENRY Gene Therapy?
The scientific name of MOGENRY is Sonpiretigene Isteparvovec. This is an optogenetic gene therapy, which has been specifically developed for severe patients with Retinitis Pigmentosa.
Usually, in gene therapy, an attempt is made to correct the bad gene responsible for the disease or to replace it with the correct gene. But MOGENRY's method is different. It attempts to give some living cells present in the retina the ability to detect light.
A special feature of this technique is that its use is not limited to disturbances in any one particular gene. Therefore, there is a possibility of its use in patients with Retinitis Pigmentosa caused due to different genetic reasons.
How does this technology work?
In MOGENRY, a special light-sensitive gene is delivered into the eye. For this, the virus that is modified and used in treatment is used as a medium. This gene helps in reaching the remaining cells of the retina and making them sensitive to light.
Photoreceptor cells in normal eyes convert light into electrical signals. These signals reach the brain through the optic nerve, where the process of seeing is completed.
In Retinitis Pigmentosa, photoreceptor cells gradually start getting destroyed. MOGENRY aims to enable the remaining cells of the retina to sense and transmit light signals. It is given through injection in the eye.
What were the results in the clinical trials?
According to the company, MOGENRY's Phase 2b/3 RESTORE clinical trial recorded improvements in some key parameters related to patients' vision. The results of the trial showed improvements in visual acuity at weeks 52 and 76.
The company also reported that no serious adverse effects related to the treatment were reported during the trial. However, these results require further evaluation and regulatory review. Positive results in clinical trials do not mean that every patient will regain their eyesight.
MOGENRY is in the process of approval in America
An important update regarding MOGENRY came out in September 2026. The US Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and filed it for review.
This means that the drug's approval process has progressed, but it has not yet received final approval for sale and routine treatment in the US. The company has also applied for this therapy in Japan, which has been accepted for review on priority basis.
How many patients can get benefit in India?
Retinitis Pigmentosa is also an important genetic eye disease in India. Some Indian studies have put its prevalence as high as one in every 1,000 people. However, this data cannot be applied equally to all states and the entire population.
The causes and severity of this disease can vary according to the genetic type of the patient. There is also interest in MOGENRY's potential use in India due to its gene-agnostic technology.
If it receives the necessary regulatory approval in the future and is made available in India, it could become a new treatment option for patients affected with severe Retinitis Pigmentosa.
At this time, it is important for patients to understand that MOGENRY is still in the testing and approval process. No firm date for its availability or commencement of treatment has been announced in India. If you experience decreased eyesight, it is important to seek examination and advice from a specialist eye doctor.